Articles tagged with Pancreatic Cancer
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers at IIT identified a candidate molecule called Apt1 that enhances existing anticancer therapies by making tumour cells more vulnerable to chemotherapy drugs. The molecule slows DNA repair and impairs the interaction between RAD51 and BRCA2 proteins, inducing synthetic lethality in cancerous cells.
Researchers developed a 13-point risk score to predict PanNET recurrence, based on male sex, tumor size, WHO grade, and lymphovascular invasion. The tool will help physicians identify high-risk patients for closer monitoring.
Researchers at UT Health San Antonio successfully used radiofrequency ablation to treat a patient with pancreatic cancer, achieving the first-ever less-invasive procedure in South Texas. The treatment has shown promising results in shrinking tumors and easing symptoms, potentially improving patient outcomes.
Researchers at the University of Houston have discovered a potential therapeutic strategy for counteracting muscle wasting in pancreatic cancer by blocking a specific cell pathway. Muscle wasting, also known as cachexia, is a debilitating syndrome affecting 60-85% of patients with pancreatic cancer.
Researchers from Okayama University and Tohoku University have identified a promising way to breach the physical and biochemical barrier created by fibrosis in pancreatic cancer. By blocking collagen signaling through DDR1, they improve drug delivery and enhance treatment response.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
Cancer researchers at Cold Spring Harbor Laboratory have identified key proteins that determine the behavior of two hard-to-treat carcinomas, pancreatic cancer and tuft cell lung cancer. These findings could lead to new therapies targeting specific vulnerabilities in these cancers.
Researchers have identified critical cellular targets to improve pancreatic tumor sensitivity to KRAS inhibitors. The team found that certain patient populations may preferentially respond to anti-KRAS and anti-EGFR combination therapies.
A new study using magnetoelectric nanoparticles successfully shrinks pancreatic tumors in preclinical models, extending survival. The Sylvester Cancer Institute has also launched its Survivorship and Supportive Care Institute to provide evidence-based care for cancer patients.
A nationwide telehealth clinical trial is now open at Ohio State University Wexner Medical Center for adults with advanced or metastatic pancreatic cancer with specific mutations in the fibroblast growth factor receptor (FGFR) gene. The study will test pemigatinib, a smart drug targeting these genetic mutations.
Researchers developed an RNA-based therapeutic strategy targeting mutant KRAS genes, stimulating the immune system to attack tumours. The treatment, combining antisense oligonucleotides and immunomodulatory RNA, effectively killed cancer cells in laboratory studies, reducing tumour burden and extending survival.
Researchers at University of Illinois Chicago have developed a microfluidic device that can isolate pancreatic cancer cells from blood samples with high accuracy. The lidocaine infusion method has shown promise in reducing the aggressiveness of circulating tumor cells and may help lower the risk of metastasis.
Researchers at UC Riverside and City of Hope have developed a novel Pin1 degrading compound that suppresses pancreatic cancer peritoneal metastases. The treatment targets not only cancer cells but also tumor-supporting cells, potentially overcoming treatment resistance.
Researchers discovered that pancreatic tumors form pseudosynapses, exploiting the body's nervous system to drive tumor growth. Calcium waves triggered by glutamate binding promote metastasis and cancer progression.
Researchers identified mild dilatation of the pancreatic duct as an early sign of pancreatic cancer in high-risk individuals, even without visible mass. This finding may lead to better survival rates if cancers are detected early through more frequent imaging.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that aging accelerates pancreatic cancer progression, leading to faster tumor growth and metastasis. By understanding the impact of age on the tumor microenvironment, they developed a new approach to treating this disease in frail patients.
Researchers developed nanomachines that can function stably within living organisms, enabling starvation therapy to treat refractory pancreatic cancer. This approach improved treatment outcomes by depleting essential nutrients for cancer cell growth.
A new study found that magnetoelectric nanoparticles can locate and destroy pancreatic tumors in preclinical models, reducing tumor size by one-third and extending survival time. The treatment uses no drugs or invasive procedures, instead guiding the nanoparticles to the tumor site using a small magnet and activating them with an MRI s...
Researchers at Northwestern University have discovered how pancreatic tumors evade the immune system and created an antibody therapy that blocks this mechanism, reawakening immune cells to attack cancer cells. The study shows promise for treating pancreatic cancer and may have broader implications for other hard-to-treat cancers.
A rare case of pancreatic Hodgkin lymphoma was reported, emphasizing the need for tissue diagnosis before definitive treatment. The patient's symptoms and imaging findings initially raised concern for pancreatic adenocarcinoma, but a biopsy revealed nodular sclerosis subtype of Hodgkin lymphoma.
Researchers at MD Anderson have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The study also identifies a new biomarker for improved immunotherapy responses in solid tumors.
Researchers at UMass Amherst have developed a nanoparticle-based vaccine that prevents melanoma, pancreatic and triple-negative breast cancer in mice. The vaccine achieved remarkable survival rates, with up to 88% of vaccinated mice remaining tumor-free.
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
Researchers at the University of Cincinnati Cancer Center have developed a new drug targeting Hsp70, a key protein aiding tumor resistance, reducing tumor size and increasing survival in animal models.
A cohort study reveals oral bacteria and fungi as significant risk factors for pancreatic cancer development. The findings suggest that oral microbiota may serve as biomarkers to identify individuals at high risk of pancreatic cancer, potentially contributing to personalized prevention strategies.
Researchers discovered that blocking two key proteins, Ref-1 and PRDX1, significantly shrunk tumors and increased cancer cell death. The approach also affected the tumor's surrounding environment, highlighting its effectiveness in disrupting the tumor's support system.
Researchers identified 27 species of bacteria and fungi that collectively increase the risk of pancreatic cancer by 3.5 times. The study analyzed saliva samples from 122,000 healthy individuals and found that boosting the mouth's microbiome may protect against cancer.
A new algorithm developed by Núria Malats and her team can accurately predict the presence of metastasis in pancreatic cancer using medical images. The PMPD algorithm has shown promising results, classifying 56% of metastases with high accuracy and potentially avoiding unnecessary surgeries.
Researchers at Salk Institute and UC San Diego have identified a unique sugar called HSAT as a potential therapeutic target for slowing tumor progression and metastasis in pancreatic ductal adenocarcinoma. Boosting HSAT levels may slow the formation and spread of pancreatic cancer, leading to improved survival rates among patients.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
Alex Arreola, a University of Oklahoma health doctoral student, has received a National Cancer Institute grant to investigate the mechanisms behind cancer cachexia, a severe weight loss syndrome prevalent in pancreatic cancer patients. He aims to understand how tumors promote early-stage weight loss and explore potential treatments.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
Researchers discovered a specific cell that responds to environmental toxins found in cigarettes, leading to aggressive tumor growth in mice with pancreatic cancer. The study also identified a type of immune cell that fuels this response while stopping the immune system from fighting tumor growth.
Breakthroughs in targeting KRAS, including promising drugs like MRTX1133 and RMC-9805, offer new hope for pancreatic cancer patients. The study explores emerging tools like PROTAC-based degraders and combination therapies involving MEK, PI3K, or CDK4/6 inhibitors to address drug resistance.
A new study finds that PAD2-mediated histone citrullination promotes tumor cell proliferation in pancreatic ductal adenocarcinoma. Knocking down the PAD2 gene reduces cell growth and increases survival rates. The researchers identify PAD inhibitors as potential therapeutic targets for treating PDAC.
A new pilot study from University Hospitals Cleveland Medical Center found that music therapy improved pain after pancreatic surgery, supporting its feasibility and acceptability. The study also suggests continued use of music-assisted relaxation recordings over the course of hospitalization to further reduce post-operative symptoms.
SRPX2 is a multifunctional protein implicated in cancer progression, neurological disorders and fibrosis, with roles in cell proliferation, migration and angiogenesis. It also interacts with genes like FOXP2 and GRIN2A, regulating language-related synaptic plasticity and cortical development.
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new model suggests that inhibiting the cellular molecule CREB might relieve damage to the pancreas and thwart tumor development in response to alcohol. The study found that knocking out CREB relieved precancerous and cancerous lesions, even with continued alcohol exposure.
A novel cancer vaccine has shown encouraging early results in patients with pancreatic and colorectal cancer, two of the most difficult-to-treat malignancies. The vaccine targets KRAS mutations found in about 25% of solid tumors and drives about 90% of pancreatic cancers and 50% of colorectal cancers.
A retrospective cohort study found that adjuvant chemotherapy improves survival in resected early-onset pancreatic cancer patients after neoadjuvant therapy. EOPC patients showed superior survival compared to average-onset pancreatic cancer, with ACT further enhancing outcomes.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
A UNLV study uses an mRNA cocktail to selectively route to the pancreas, reducing the risk of immune responses and side effects. The breakthrough offers new hope for treating pancreas-related diseases, including cancer and diabetes.
Researchers developed a software fueled by genomics to predict cancer cell behavior, combining genomics technologies with computational modeling. The new 'grammar' enables communication between biology and code, allowing scientists to build digital representations of multicellular biological systems and simulate diseases like cancer.
Researchers at Sanford Burnham Prebys found that blocking macropinocytosis reshapes the tumor microenvironment, allowing more access to immune cells. This change made immunotherapy and chemotherapy more effective in treating PDAC tumors in mice.
Diana Hargreaves will receive $1 million to advance her project on improving immunotherapy in patients with pancreatic cancer. Her previous work identified better drug targets for cancers with SWI/SNF mutations, leading to breakthroughs in treating difficult-to-treat cancers.
Researchers at Fralin Biomedical Research Institute have identified a potential target for experimental drugs that block PRMT5, a naturally occurring enzyme some tumors rely on for survival. The study found a new drug combination that works against certain hard-to-treat cancers.
A new case report describes the use of extracorporeal blood filtration to treat stage IV poorly differentiated pancreatic adenocarcinoma. The patient experienced clinical improvement, reduced pain, and no signs of new tumor growth over 12 months of follow-up.
A recent national study reveals complex patterns of burden and survival trends for digestive system malignancies (DSMTs) in China. Despite progress in reducing mortality from some cancers, the overall impact remains significant, with notable disparities across demographic and geographic lines.
Early-onset gastrointestinal cancers are rising globally, particularly among younger adults. Colorectal cancer is the most common early-onset GI cancer, accounting for over half of cases, and its incidence is increasing faster than any other type of early-onset cancer.
Researchers at MD Anderson identified specific co-mutations in KRAS-mutant non-small cell lung cancer (NSCLC) that improve treatment response to ATR inhibitors. Additionally, chemotherapy was found to drive changes to the genome and clonal architecture of blood stem cells, increasing the risk of secondary malignancies.
Researchers used AI model ChatGPT-4 to extract clinical variables from MRI and CT scans of nearly 1,000 adults with pancreatic cysts. The accuracy rate ranged from 97% for solid components to 99% for calcific lesions, comparable to human performance.
The Damon Runyon Cancer Research Foundation has awarded $4.2 million to five new Clinical Investigators conducting patient-oriented cancer research. The awards will support the development of new treatments for cancer patients, with a focus on enhancing efficacy and safety.
Researchers at Fujita Health University discovered benzaldehyde's mechanism to halt therapy-resistant pancreatic cancer growth and spread. Benzaldehyde prevents key interactions that enable cancer cells' survival and treatment resistance.